BioVersys AG (Ticker: BIOV SW) is a Swiss pharmaceutical company focusing on the research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation.

BioVersys AG will list on February 7, 2025, on the SIX Swiss Exchange. The firm is selling 2.08 million shares at the price of CHF 36.00 (USD 39.6792). The expected Market Capitalization at offer is CHF 212.9 million (USD equivalent not provided). The total offer size is CHF 75.00 million (USD 82.66 million). The offering is managed by Citi, UBS, and Stifel as joint global coordinators, with Octavian and Mirabaud as selling agents. The proceeds will be used for the development of its lead asset, BV100, and its second lead asset, Alpibectir, and the remaining proceeds are expected to be allocated to the Company’s preclinical pipeline.